Pharmacists: Bispecifics and Operational Role

EP: 1.Bispecific Antibodies in DLBCL: Therapeutic Potential

EP: 2.Efficacy Insights on Bispecific Antibodies in DLBCL

EP: 3.Bispecific Antibodies in DLBCL Trials

EP: 4.Bispecific Antibodies in DLBCL: Patient Response

EP: 5.Future Insights on Bispecific Therapies

EP: 6.Overcoming DLBCL Treatment Hurdles

EP: 7.Patient Education and Monitoring in DLBCL Treatment

EP: 8.Implementing Bispecific Treatments

EP: 9.Bispecific Toxicity Management in DLBCL Care

EP: 10.Multidisciplinary Bispecific Care

Now Viewing

EP: 11.Pharmacists: Bispecifics and Operational Role

EP: 12.Strategies for Reducing Bispecific Therapy Toxicities

EP: 13.Unmet Needs in Bispecific Therapy Access

EP: 14.Implementing Bispecific Antibodies in Lymphoma Care

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.

In this segment, Mahmoudjafari and Mancini discuss the crucial role of pharmacists in operationalizing the utilization of bispecifics in lymphomas. Mancini emphasizes the pharmacist’s role as a quarterback on the multidisciplinary team, executing plays called by oncologists and bridging gaps among education, operationalization, and clinical support. He highlights the uniqueness of these drugs and how pharmacists can lead in getting them into practice, ensuring ethical, financial, and operational aspects are met.

The discussion delves into the pharmacist’s responsibility in building treatment plans within the patient chart, including communication orders, supportive care medications, and lab work. Mancini stresses the pharmacist’s essential role in overcoming operational challenges, with a focus on pharmacy and therapeutics approval, education protocols, patient materials, and involvement in algorithms and toxicity management protocols.

Mahmoudjafari acknowledges the pharmacist’s contribution in operationalizing and highlights their involvement in various aspects such as P&T approval, education protocols, and patient materials, emphasizing the pharmacist’s versatility and crucial role in optimizing bispecific antibody treatments.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.